Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Better options available for MDR

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Mar 20, 2021 8:28pm

158 Views

Post# 32845976

RE:Better options available for MDR

Question for the science members, if someone is infected with HIV from an advanced MDR individual will they be at the same MDR level? It seems like that’s the way it would work, sure would be a horrible way to start one’s battle with HIV.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023